Bioatla reports second quarter 2023 financial results and highlights recent progress

San diego, aug. 01, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the second quarter ended june 30, 2023, and provided highlights on its clinical programs.
BCAB Ratings Summary
BCAB Quant Ranking